LFST
Bullish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Supports a bullish reading. Current ratio 1.65 · operating margin 1.7%
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Unavailable or mixed. No stored price series
VENTE TOTALE: 527 941 titres (~6 100 093,43 $ US)
- Insiders
- DeLuca TeresaBurdick Kenneth A
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$6,100,093
Avg sell (VWAP, 90d window) $11.54 vs last close —
- Last activity
- 2026-08-14
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-02 | Paunovich Vukasin | Sell | 42,067 | $12.87 | $541,402 | Form 4 |
| 2026-08-14 | DeLuca Teresa | Sell | 7,500 | $12.68 | $95,100 | Form 4 |
| 2026-08-13 | DeLuca Teresa | Sell | 20,441 | $12.23 | $249,993 | Form 4 |
| 2026-08-11 | Burdick Kenneth A | Sell | 500,000 | $11.51 | $5,755,000 | Form 4 |
| 2026-08-10 | Miller Lisa K | Sell | 47,912 | $10.85 | $519,845 | Form 4 |
| 2026-08-10 | Paunovich Vukasin | Sell | 44,394 | $10.85 | $481,675 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bullish signalScored 2026-09-06
LFST presents a compelling turnaround story with strong liquidity (80) and improving fundamentals (75), supported by a Q2 2026 earnings beat and a BTIG price target upgrade pushing the stock to new 52-week highs.
The first sentence of the analysis written for LFST on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 32.4% | 32.2% | 28.6% | 27.6% | 30.2% | |
| Ebit Margin | 1.7% | -2.5% | -17.6% | -24.8% | -44.1% | |
| Ebitda Margin | 5.5% | 3.2% | -9.9% | -16.7% | -36.0% | |
| Operating Profit Margin | 1.7% | -2.5% | -17.9% | -24.5% | -42.9% | |
| Pretax Profit Margin | 0.9% | -4.6% | -19.6% | -27.1% | -49.9% | |
| Continuous Operations Profit Margin | 0.7% | -4.6% | -17.6% | -25.1% | -46.0% | |
| Net Profit Margin | 0.7% | -4.6% | -17.6% | -25.1% | -46.0% | |
| Bottom Line Profit Margin | 0.7% | -4.6% | -17.6% | -25.1% | -51.5% | |
| Current Ratio | 1.652 | 1.365 | 1.113 | 1.325 | 2.283 | |
| Quick Ratio | 1.652 | 1.365 | 1.113 | 1.325 | 1.957 | |
| Solvency Ratio | 0.094 | 0.020 | -0.155 | -0.223 | -0.662 | |
| Cash Ratio | 0.987 | 0.675 | 0.389 | 0.617 | 1.268 | |
| Price To Earnings Ratio | 234.667 | -49.133 | -15.353 | -8.098 | -9.067 | |
| Price To Earnings Growth Ratio | -1.956 | 0.696 | 0.937 | 0.193 | -0.342 | |
| Forward Price To Earnings Growth Ratio | -1.956 | 0.696 | 0.937 | 0.193 | -0.342 | |
| Price To Earnings Diluted Ratio | 352.000 | -49.133 | -15.353 | -8.098 | -9.067 | |
| Price To Earnings Diluted Growth Ratio | -3.106 | 0.696 | 0.937 | 0.193 | -0.342 | |
| Price To Book Ratio | 1.787 | 1.932 | 2.014 | 1.156 | 2.018 | |
| Price To Sales Ratio | 1.908 | 2.234 | 2.725 | 2.042 | 4.671 | |
| Price To Free Cash Flow Ratio | 24.699 | 32.608 | -50.122 | -66.314 | -36.652 | |
| Price To Operating Cash Flow Ratio | 18.594 | 26.052 | -170.409 | 33.247 | 331.000 | |
| Debt To Assets Ratio | 0.088 | 0.229 | 0.242 | 0.220 | 0.082 | |
| Debt To Equity Ratio | 0.128 | 0.335 | 0.358 | 0.315 | 0.103 | |
| Debt To Capital Ratio | 0.113 | 0.251 | 0.263 | 0.240 | 0.093 | |
| Long Term Debt To Capital Ratio | 0.089 | 0.162 | 0.164 | 0.129 | 0.092 | |
| Financial Leverage Ratio | 1.449 | 1.465 | 1.477 | 1.431 | 1.247 | |
| Working Capital Turnover Ratio | 11.493 | 23.496 | 26.365 | 8.305 | 8.893 | |
| Operating Cash Flow Ratio | 0.580 | 0.469 | -0.083 | 0.300 | 0.081 | |
| Operating Cash Flow Sales Ratio | 0.103 | 0.086 | -0.016 | 0.061 | 0.014 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.753 | 0.799 | 3.400 | -0.501 | -9.031 | |
| Debt Service Coverage Ratio | 1.330 | 1.185 | -3.504 | -5.677 | -5.323 | |
| Interest Coverage Ratio | 2.071 | -1.191 | -8.913 | -10.547 | -7.359 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.209 | 14.794 | -5.772 | 22.511 | 7.120 | |
| Operating Cash Flow Coverage Ratio | 0.753 | 0.221 | -0.033 | 0.110 | 0.059 | |
| Capital Expenditure Coverage Ratio | 4.046 | 4.974 | -0.417 | 0.666 | 0.100 | |
| Dividend Paid And Capex Coverage Ratio | 4.046 | 4.974 | -0.417 | 0.666 | 0.100 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 33.804 | 78.374 | -31.540 | -14.800 | -13.033 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 32.4% | ▲0.2% | ▲2.2% |
| Ebit Margin | 1.7% | ▲4.2% | ▲19.1% |
| Ebitda Margin | 5.5% | ▲2.3% | ▲16.3% |
| Operating Profit Margin | 1.7% | ▲4.2% | ▲18.9% |
| Pretax Profit Margin | 0.9% | ▲5.5% | ▲20.9% |
| Continuous Operations Profit Margin | 0.7% | ▲5.3% | ▲19.2% |
| Net Profit Margin | 0.7% | ▲5.3% | ▲19.2% |
| Bottom Line Profit Margin | 0.7% | ▲5.3% | ▲20.3% |
| Current Ratio | 1.652 | ▲0.286 | ▲0.104 |
| Quick Ratio | 1.652 | ▲0.286 | ▲0.170 |
| Solvency Ratio | 0.094 | ▲0.074 | ▲0.280 |
| Cash Ratio | 0.987 | ▲0.311 | ▲0.200 |
| Price To Earnings Ratio | 234.667 | ▲283.800 | ▲204.064 |
| Price To Earnings Growth Ratio | -1.956 | ▼-2.652 | ▼-1.861 |
| Forward Price To Earnings Growth Ratio | -1.956 | ▼-2.652 | ▼-1.861 |
| Price To Earnings Diluted Ratio | 352.000 | ▲401.133 | ▲297.930 |
| Price To Earnings Diluted Growth Ratio | -3.106 | ▼-3.802 | ▼-2.781 |
| Price To Book Ratio | 1.787 | ▼-0.145 | ▲0.005 |
| Price To Sales Ratio | 1.908 | ▼-0.326 | ▼-0.808 |
| Price To Free Cash Flow Ratio | 24.699 | ▼-7.909 | ▲43.855 |
| Price To Operating Cash Flow Ratio | 18.594 | ▼-7.458 | ▼-29.103 |
| Debt To Assets Ratio | 0.088 | ▼-0.141 | ▼-0.084 |
| Debt To Equity Ratio | 0.128 | ▼-0.208 | ▼-0.120 |
| Debt To Capital Ratio | 0.113 | ▼-0.138 | ▼-0.079 |
| Long Term Debt To Capital Ratio | 0.089 | ▼-0.073 | ▼-0.038 |
| Financial Leverage Ratio | 1.449 | ▼-0.016 | ▲0.035 |
| Working Capital Turnover Ratio | 11.493 | ▼-12.004 | ▼-4.218 |
| Operating Cash Flow Ratio | 0.580 | ▲0.111 | ▲0.311 |
| Operating Cash Flow Sales Ratio | 0.103 | ▲0.017 | ▲0.053 |
| Free Cash Flow Operating Cash Flow Ratio | 0.753 | ▼-0.046 | ▲1.669 |
| Debt Service Coverage Ratio | 1.330 | ▲0.145 | ▲3.728 |
| Interest Coverage Ratio | 2.071 | ▲3.262 | ▲7.259 |
| Short Term Operating Cash Flow Coverage Ratio | 3.209 | ▼-11.585 | ▼-5.163 |
| Operating Cash Flow Coverage Ratio | 0.753 | ▲0.532 | ▲0.531 |
| Capital Expenditure Coverage Ratio | 4.046 | ▼-0.928 | ▲2.172 |
| Dividend Paid And Capex Coverage Ratio | 4.046 | ▼-0.928 | ▲2.172 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 33.804 | ▼-44.570 | ▲23.243 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.72B | $2.79B | $2.88B | $1.76B | $3.12B | |
| Enterprise value | $2.66B | $3.12B | $3.31B | $2.13B | $3.13B | |
| EV / Sales | 1.87x | 2.50x | 3.13x | 2.47x | 4.69x | |
| EV / Op. cash flow | 18.22x | 29.13x | -196.01x | 40.26x | 332.14x | |
| EV / Free cash flow | 24.20x | 36.47x | -57.65x | -80.30x | -36.78x | |
| EV / EBITDA | 33.80x | 78.37x | -31.54x | -14.80x | -13.03x | |
| Net debt / EBITDA | -0.69x | 8.29x | -4.12x | -2.58x | -0.04x | |
| Current ratio | 1.65x | 1.36x | 1.11x | 1.32x | 2.28x | |
| Income quality | 15.12x | -1.87x | 0.09x | -0.24x | -0.03x | |
| Graham number | $1 | — | — | — | — | |
| Graham net-net | -$1 | -$1 | -$1 | -$1 | -$0 | |
| Tax burden | 78.2% | 99.7% | 90.2% | 92.6% | 92.2% | |
| Interest burden | 51.5% | 185.4% | 111.4% | 109.4% | 113.2% | |
| Working capital | $164.2M | $83.6M | $22.9M | $57.2M | $149.8M | |
| Invested capital | $1.95B | $1.88B | $1.90B | $1.99B | $1.81B | |
| Return on assets | 0.4% | -2.7% | -8.8% | -9.9% | -15.9% | |
| Operating ROA | 1.1% | -1.5% | -8.8% | -10.2% | -16.4% | |
| Return on tangible assets | 1.3% | -9.1% | -31.3% | -33.8% | -72.8% | |
| Return on equity | 0.6% | -4.0% | -13.0% | -14.2% | -19.9% | |
| Return on invested capital | 0.9% | -1.6% | -8.7% | -9.5% | -14.6% | |
| Return on capital employed | 1.2% | -1.7% | -9.9% | -10.5% | -15.8% | |
| Earnings yield | 0.4% | -2.1% | -6.5% | -12.3% | -9.9% | |
| Free cash flow yield | 4.0% | 3.1% | -2.0% | -1.5% | -2.7% | |
| Capex / Op. cash flow | 24.7% | 20.1% | -240.0% | 150.1% | 1003.1% | |
| Capex / Depreciation | 66.0% | 30.4% | 50.4% | 114.5% | 174.5% | |
| Capex / Sales | 2.5% | 1.7% | 3.8% | 9.2% | 14.2% | |
| SG&A / Sales | 26.8% | 29.0% | 38.9% | 44.0% | 65.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 5.2% | 6.1% | 9.4% | 21.8% | 38.9% | |
| Intangibles / Total assets | 66.7% | 70.1% | 71.8% | 70.7% | 78.1% | |
| Days sales outstanding | 25d | 39d | 43d | 43d | 54d | |
| Days payables outstanding | 2d | 3d | 11d | 14d | 11d | |
| Operating cycle | 25d | 39d | 43d | 43d | 84d | |
| Cash conversion cycle | 22d | 35d | 32d | 29d | 73d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-2.7%EV / Sales ▼-25.2%EV / EBITDA ▼-56.9%EV / Op. cash flow ▼-10.913Earnings yield ▲+0.024
Profitability
Return on equity ▲+0.046Return on assets ▲+0.032Return on invested capital ▲+0.026Return on capital employed ▲+0.029Operating ROA ▲+0.026Income quality ▲+16.992Tax burden ▼-0.215
Efficiency
Days sales outstanding ▼-13.994Days payables outstanding ▼-0.795Operating cycle ▼-13.994Cash conversion cycle ▼-13.199Capex / Sales ▲+0.008R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.286Net debt / EBITDA ▼-8.984Working capital ▲+80614000.000Invested capital ▲+64864000.000Intangibles / Total assets ▼-0.033
Change over 5 years
Valuation
Market cap ▼-12.8%EV / Sales ▼-60.1%EV / EBITDA ▲+359.4%EV / Op. cash flow ▼-313.916Earnings yield ▲+0.102
Profitability
Return on equity ▲+0.205Return on assets ▲+0.164Return on invested capital ▲+0.155Return on capital employed ▲+0.171Operating ROA ▲+0.175Income quality ▲+15.155Tax burden ▼-0.141
Efficiency
Days sales outstanding ▼-29.775Days payables outstanding ▼-8.765Operating cycle ▼-59.595Cash conversion cycle ▼-50.830Capex / Sales ▼-0.116R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.631Net debt / EBITDA ▼-0.648Working capital ▲+14470000.000Invested capital ▲+139643000.000Intangibles / Total assets ▼-0.113
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-08-13 LifeStance Health Group (LFST) Is Up 3.44% in One Week: What You Should Know Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-08-12 5 Low-Leverage Stocks to Buy as High Oil Prices Shake Investor Confidence High oil prices and market volatility spotlight five low-leverage stocks with strong earnings growth and resilient balance sheets.
- 2026-08-11 LifeStance Health (LFST) Upgraded to Buy: Here''s Why LifeStance Health (LFST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company''s earnings prospects. This might drive the stock higher in the near term.
- 2026-08-11 LifeStance Health Group, Inc. (LFST) Soars to 52-Week High, Time to Cash Out? LifeStance Health (LFST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company''s fundamentals for clues.
- 2026-08-11 LifeStance Survey Finds Women Want Mental Healthcare Built Into Perimenopause and Menopause Care One in Three Women Don''t Know Perimenopause Can Cause Anxiety, Depression and Mood Changes; Majority Who Seek Mental Healthcare Find It Helpful SCOTTSDALE, Ariz., Aug. 11, 2026 /PRNewswire/ -- A LifeStance Health survey of 1,000 women experiencing perimenopause or menopause released today reveals this life stage carries an unexpected mental health toll, as one in three women (33%) report being unaware that perimenopause can cause mental health-related symptoms.
- 2026-08-11 LifeStance Health Group (NASDAQ:LFST) Sets New 1-Year High After Analyst Upgrade LifeStance Health Group, Inc. (NASDAQ: LFST - Get Free Report)''s stock price reached a new 52-week high during trading on Monday after BTIG Research raised their price target on the stock from $15.00 to $16.00. BTIG Research currently has a buy rating on the stock. LifeStance Health Group traded as high as $12.06 and last traded
- 2026-08-06 LifeStance Health Group Q2 Earnings Call Highlights LifeStance Health Group NASDAQ: LFST reported second-quarter results that exceeded its prior expectations, driven by higher visit volumes, increased revenue per visit and continued clinician productivity gains. The outpatient mental health provider raised its full-year revenue, Center Margin and adjusted EBITDA guidance.
- 2026-08-06 LifeStance Health Group, Inc. (LFST) Q2 2026 Earnings Call Transcript LifeStance Health Group, Inc. (LFST) Q2 2026 Earnings Call Transcript
- 2026-08-06 LifeStance Health Group (LFST) Tops Q2 Earnings and Revenue Estimates LifeStance Health Group (LFST) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.01 per share a year ago.
- 2026-08-06 LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation''s largest providers of outpatient mental healthcare, today announced financial results for the second quarter ended June 30, 2026.